Diviplus

(6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator.

Medroxyprogesterone (Diviplus) is a progestin (a form of progesterone), a female hormone that helps regulate ovulation (the release of an egg from an ovary) and menstrual periods.

Medroxyprogesterone (Diviplus) is used to treat conditions such as absent or irregular menstrual periods, or abnormal uterine bleeding. Medroxyprogesterone (Diviplus) is also used to decrease the risk of endometrial hyperplasia (a condition that may lead to uterine cancer) while taking estrogens.

Medroxyprogesterone (Diviplus) is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy.

Estradiol (Diviplus) and Medroxyprogesterone (Diviplus) contains a combination of female hormones that prevent ovulation (the release of an egg from an ovary). This medication also causes changes in your cervical mucus and uterine lining, making it harder for sperm to reach the uterus and harder for a fertilized egg to attach to the uterus.

Estradiol (Diviplus) and Medroxyprogesterone (Diviplus) is used as contraception to prevent pregnancy.

Estradiol (Diviplus) and Medroxyprogesterone (Diviplus) may also be used for other purposes not listed in this medication guide.

Applies to the following strengths: 5 mg-25 mg/0.5 mL

Usual Adult Dose for:

• Contraception

Usual Adult Dose for Contraception

0.5 mL administered by intramuscular injection, into the deltoid, gluteus maximus, or anterior thigh. The first injection should be within the first 5 days of the onset of a normal menstrual period, or within 5 days of a complete abortion, but not earlier than 4 weeks postpartum if not breast-feeding, or 6 weeks postpartum if breast-feeding.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Diviplus

• Diviplus Side Effects
• During Pregnancy
• Drug Interactions
• Drug class: contraceptives

Consumer resources

• Estradiol (Diviplus) and Medroxyprogesterone (Diviplus)

  Intramuscular (Advanced Reading)

Other brands: Diviplus

Related treatment guides

• Birth Control

See also:
What is the most important information I should know about Diviplus?

COUNTRA

Indications:

Previous history of hypersensitivity (allergic) to tiotropium bromide, atropine or to its derivatives (ipratropium or oxytropium) or lactose (excipient which contains milk proteins).

NOT RECOMMENDED:

- Pediatric Use: The safety and efficacy of tiotropium bromide powder inhalation capsule, have not been established in pediatric patients. Therefore, its use is not recommended in patients under 18 years.

- Pregnancy and lactation: No clinical data is available on a documented exposure to tiotropium bromide occurred during pregnancy. Studies in animals have shown reproductive toxicity associated with maternal toxicity. The potential risk for humans is unknown. SPIRIVA should therefore be administered during pregnancy only if the indication is clearly justified. It was not known whether tiotropium bromide is excreted in breast milk. Despite studies in rodents have shown that tiotropium bromide is excreted in breast milk only in small quantities, the use of Spiriva is not recommended during breastfeeding. Tiotropium bromide is a compound with long duration of action. The decision to continue or discontinue breast-feeding or treatment with SPIRIVA should be made taking into account the benefit of breastfeeding in children and treatment benefit in women with SPIRIVA.

- Co-administration of tiotropium bromide with other anticholinergic drugs has not been studied and is therefore not recommended. narrow-angle glaucoma; or

an enlarged prostate or a bladder obstruction

This medication is given as an injection into a muscle in your upper arm, thigh, or buttocks. You will receive this injection in your doctor's office or other clinic setting. Before receiving your first injection, tell your doctor about all other forms of birth control you have used within the past 7 days.

The first injection of this medication is given during the first 5 days of a normal menstrual period, or within 5 days after undergoing a complete first-trimester abortion.

After your first injection, you will need to receive monthly injections every 28 to 30 days to assure prevention of pregnancy. Do not allow more than 33 days to pass between injections, even if your menstrual period has started later than expected.

Tell your doctor if your period has not started by the time you are due for your monthly injection.

If you need to have any type of medical tests or surgery, or if you will be on bed rest, you may need to stop using this medication for a short time. Any doctor or surgeon who treats you should know that you are using birth control injections.

Your doctor will need to see you on a regular basis while you are using this medication. Do not miss any appointments.

See also:
What other drugs will affect Diviplus?

No drug-drug interaction studies have been conducted with depo-subQ provera 104.

Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA.

Laboratory Tests

The pathologist should be advised of progestin therapy when relevant specimens are submitted. The physician should be informed that certain endocrine and liver function tests, and blood components may be affected by progestin therapy:

(a) Plasma and urinary steroid levels are decreased (e.g., progesterone, Estradiol (Diviplus), pregnanediol, testosterone, cortisol).

(b) Plasma and urinary gonadotropin levels are decreased (e.g., LH, FSH).

(c) SHBG concentrations are decreased.

(d) T₃-uptake values may decrease.

(e) There may be small changes in coagulation factors.

(f) Sulfobromophthalein and other liver function test values may be increased slightly.

(g) There may be small changes in lipid profiles.

See also:
What are the possible side effects of Diviplus?

Applies to Estradiol (Diviplus) / Medroxyprogesterone (Diviplus): intramuscular oil

In addition to its needed effects, some unwanted effects may be caused by Estradiol (Diviplus) / Medroxyprogesterone (Diviplus). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking Estradiol (Diviplus) / Medroxyprogesterone (Diviplus):

More common:

• Bloating or swelling of face, hands, lower legs and/or feet
• cough
• difficulty swallowing
• dizziness
• fast heartbeat
• hives
• itching
• loss of appetite and nausea
• puffiness or swelling of the eyelids or around the eyes, face, lips or tongue
• rapid weight gain
• shortness of breath
• tightness in chest
• unusual tiredness or weakness
• vomiting blood
• wheezing
• yellow eyes or skin

• Nausea
• menstrual irregularities
• vaginal bleeding
• vomiting

Minor Side Effects

Some of the side effects that can occur with Estradiol (Diviplus) / Medroxyprogesterone (Diviplus) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:

• Abdominal pain or enlarged abdomen
• absent or missed menstrual periods
• acne
• allergic rash
• brown, blotchy spots on skin
• decreased sex drive
• depression
• hair loss/thinning of hair
• headache
• increased amount of menstrual bleeding, or normal bleeding that comes earlier
• lack or loss of strength

• nervousness
• quick to react or overact emotionally
• rapidly changing moods
• stopping of menstrual bleeding over several months
• vaginal yeast infection
• weight change